SITC_Friday_2017_Khaaliq_Thomas-21.jpgThe SITC 2017 Microlearning: Clinical Trials - New Agents Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field.  


The Clinical Trials - New Agents series contains four modules. 

 

 

Module 1: First-in-Human Study With Intratumoral Administration of a CD40 Agonistic Antibody: Preliminary Results With ADC-1013/JNJ-64457107 in Advanced Solid Malignancies

Peter Ellmark, PhD - Alligator Bioscience


Module 2: Initial Results from Phase 1 Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with NSCLC Refractory or Resistant to Prior Anti–PD-1/Anti–PD-L1 Agents

James L. Gulley, MD, PhD, FACP - National Cancer Institute


Module 3: A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients (pts) with Advanced Solid Tumors

Glen J. Weiss, MD - Western Regional Medical Center Inc.


Module 4: A Dual and Opposing Role for Tumor Intrinsic Type-II Interferon Sensing in Tumor Establishment and Acquired Resistance

Jason Williams, BS - University of Chicago

 

 

Target Audience

These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.

 

Course Available Beginning: August 16, 2018

 

 

Course Objectives
Upon completion of this activity, participants will be able to:
  • Describe the immune mechanisms that new immunotherapy agents are targeting.
  • Outline how new IO agents work to circumvent cancer immune resistance mechanisms.
  • Define the immune response generated by new IO agents.
Register Now
In order to access this program after registering, a SITC account will be provided for you based on the information you have entered.

To access your account after your purchase, use the My Account links on the left hand side of this page to login using the information your provide here.
According to our records there is already a SITC account using the email address you have provided.

To continue with your registration please enter your account password. If you do not know your account password you can retrieve it here: Forgot Password?
First Name:
Last Name:
Email:
Confirm Email:
Which degree best describes you? :
Other degree, please describe:
What is your professional role? (If more than one applies to you, type additional roles below):
Other professional role, please describe:
If more than one professional role applies to you, please enter the additional roles here:
Which of the following best describes your primary work setting? :
Other primary work setting, please describe: :
What is your area of specialization?:
Other area of specialization, please describe::
Product:
SITC 2017 Microlearning: Clinical Trials: New Agents Series
The email address you have entered has an existing SITC account.

Please enter your password in the field below. Forgot Password?

Email:
Password:
Country:
Billing Address:
City:
State:
State/Province:
Zip:
Expiration: 
Pre-Test: Module 1

Before beginning the presentation, please complete the brief pre-test questions.

Module 1: First-in-Human Study With Intratumoral Administration of a CD40 Agonistic Antibody: Preliminary Results With ADC-1013/JNJ-64457107 in Advanced Solid Malignancies

The SITC 2017 Microlearning: Clinical Trials - New Agents Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017)This is the first of four modules in the SITC 2017 Microlearning: Clinical Trials - New Agents Series. You may complete any of the modules in the order you choose. 

Speaker Information
Peter Ellmark, PhD  [ view bio ]
Pre-Test: Module 2

Before beginning the presentation, please complete the brief pre-test questions.

Module 2: Initial Results from Phase 1 Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF-beta, in Patients with NSCLC Refractory or Resistant to Prior Anti-PD-1/Anti-PD-L1 Agents

The SITC 2017 Microlearning: Clinical Trials - New Agents Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017)This is the second of four modules in the SITC 2017 Microlearning: Clinical Trials - New Agents Series.

Speaker Information
James L. Gulley, MD, PhD, FACP  [ view bio ]
Pre-Test: Module 3

Before beginning the presentation, please complete the brief pre-test questions.

Module 3: A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients (pts) with Advanced Solid Tumors

The SITC 2017 Microlearning: Clinical Trials - New Agents Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017)This is the third of four modules in the SITC 2017 Microlearning: Clinical Trials - New Agents Series.

Speaker Information
Thomas Powles, MBBS, MRCP, MD  [ view bio ]
Pre-Test: Module 4

Before beginning the presentation, please complete the brief pre-test questions.

Module 4: A Dual and Opposing Role for Tumor Intrinsic Type-II Interferon Sensing in Tumor Establishment and Acquired Resistance

he SITC 2017 Microlearning: Clinical Trials - New Agents Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). This is the final of four modules in the SITC 2017 Microlearning: Clinical Trials - New Agents Series.

Speaker Information
Jason Williams, BS  [ view bio ]
Individual topic purchase: Selected